http://247wallst.com/2009/07/22/the-next...

We started by identifying the top sellers in each of the top 10 conditions, then looked at promising candidates that threaten to one day supplant the market leaders

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market.

(sounds like Afresa to me top line data and may stop progression of diabetes! and zero hypos when used alone!!!!)

INSULIN AND DIABETES TREATMENTS:

The U.S. Centers for Disease Control says that $116 billion was spent on treating diabetes in the U.S. in 2007. And because it’s a disease where a quarter of the 23.6 million affected are unaware that they have it, sales of these treatments may soon climb under proposed health care reform plans.

(National Health Care just passed the house!!!)

The Potential Blockbusters:

The true up-and-comer, however, may be an inhalable biopharmaceutical insulin candidate from Mannkind Corp. (Nasdaq: MNKD) called Afresa. It’s true that inhalable insulin has been under development for a long time that has had issues from the start. But MannKind shares recently posted a new 52-week high on Afresa study data. In a late-stage study, the Valencia, Calif.-based company said Afresa’s performance was shown to be comparable to injectable insulin.

Expectations are rising that Mankind may soon secure a worldwide marketing and development partner for Alfresa, and that it likely will be an approved product by next spring.

One possible partner might be Pfizer Inc (NYSE: PFE), which started switching its Exubera inhaled-insulin patients to MannKind’s experimental product. The companies had been partners until Pfizer pulled Exubera from the market in 2007 after showing poor sales.

4. IMMUNE SYSTEM BOOSTERS/SUPRESSANTS

About $20.7 billion is expected to be spent on immune system modulators in 2009, a number that is expected to grow as the number of treatments that work with the body’s immune system increases.

Cancer kills about 1,500 people a day in the U.S., more all conditions other than heart disease. And according to the American Cancer Society, it accounts for nearly one of every four deaths. That said, there are more than 3 times the number of cancer survivors in the U.S. today than in 1970,

I put the last two in sort of order for the MKC1106 line ups.. we are talking mega company here suplanting the other companies..this thing is so massive I am shocked it is not seen clearly as I see it..
Every drug Mannkind is making is a Block Buster! imo and not just mine!
They have hit every target with Afresa..I mean really besides others failures Afresa is not had any failures! NOT ONE! in FACT it has had suprizing advancements! Zero Hypos! UNHEARD OF BEFORE! Weight loss! Stops Progression of Diabetes!!! 12-14 min to action out of body in 3 hrs!! inhale it not a shot!! Are analyst incredibly stupid? The analsyst look to be the clowns moreso then I, and we will see who laughs last..